Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study

NCT07746895 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT07746895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07746895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 4
Overall status
Recruiting
Start date
August 5, 2026
Completion date
January 31, 2032
Enrollment
150 (estimated)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

c3 glomerulopathy (c3g), immune complex membranoproliferative glomerulonephritis (ic-mpgn)